Currently, we are using the optimum RT dose and cannot increase any further due to the toxicity associated with surrounding normal tissue. Therefore, our approach is to introduce radiosensitizing agents to tumor cells to enhance the RT dose. Recent clinical trials show better survival in prostate cancer patients with a combined treatment of radiotherapy (RT) […]
Read More